Biosense Webster Begins Enrollment of Pivotal Trial Evaluating the Laminar Left Atrial Appendage Elimination Device

Investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation 

Related Keywords

United States ,Arkansas ,California ,Jonesboro ,Los Robles ,Saibal Kar ,Johnson Medtech ,Jennifer Currin ,Devi Nair ,Johnson Medtechi ,Laminar Inc ,Scientific Affairs ,Healthcare National Physician ,Los Robles Health System ,Electrophysiology Division ,Bernard Heart Vascular Center ,Biosense Webster Inc ,Cardiovascular Specialty Solutions At Johnson Medtech ,Biosense Webster ,Laminar Left Atrial Appendage Elimination ,Program Director ,Cardiovascular Disease Fellowship ,National Physician Director ,Interventional Cardiology ,Cardiac Electrophysiology Division ,Vascular Center ,Principal Investigator ,Feasibility Study ,Vice President ,Specialty Solutions ,Early Feasibility Study ,